Senior Director, Economic Modeling at Revolution Medicines

You're a seasoned leader with at least 15 years of experience in economic modeling within the pharmaceutical, biotech, or consulting sectors, holding an advance

Work type: hybrid

Location: Redwood City, California, United States

Salary: $244,000 – $305,000/yr

Type: Full-time

Summary

You're a seasoned leader with at least 15 years of experience in economic modeling within the pharmaceutical, biotech, or consulting sectors, holding an advanced degree in a quantitative field like health economics or biostatistics. **What makes it worth a look...** Revolution Medicines, a late-stage clinical oncology company, is offering a full-time, hybrid role in Redwood City, California, with a compelling salary range of USD 244,000 - 305,000 annually. **You might be a good fit if you...** * Have hands-on experience developing cost-effectiveness and budget impact models, including NMA/MAIC. * Can direct statistical analyses of real-world and clinical trial data. * Have a track record of high-impact publications for global access decision-makers. * Possess proven leadership and the ability to influence without direct reporting lines.

Job Description

Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway.

The Opportunity:

The Senior Director of Economic Modeling is responsible for defining and executing the economic modeling strategy to produce high quality health economic models & modeling strategies across Rev Meds portfolio. This is an exceptional opportunity to contribute to the advancement of healthcare by providing evidence that can shape the future of patient care in Oncology.

Key Strategic Responsibilities:

• Lead the development of strategic and operational plans for health economic modeling within Global HEOR & RWE (e.g., early and submission cost-effectiveness / utility models, budget impact models, and country adaptations) while ensuring alignment with Integrated Evidence Plans and appropriate Global stakeholders.

• Partner with Global HEOR & RWE Executive Directors on core health economic modeling plans to support HTA, payer, and other access stakeholder assessments, submissions, negotiations, including associated value/HTA deliverables and publications to meet business and access objectives.

• Provide strategic, methodological and analytical leadership to teams and countries for adaptation of economic models for local HTA submissions

• Lead the development of an approach to monitor, educate and integrate evolving HTA guidelines, payer requirements, and methodologic advancements related to economic modeling.

• Lead the development of robust governance, compliance, and readiness for all economic modeling activities by adhering to processes, guidelines, and project management standards.

• Represent Rev Med in global external working groups regarding modeling standards and innovation (e.g., ISPOR Special Interest groups).

• Support design and development of economic models from start to finish for products across Rev Meds portfolio.

• Direct statistical analyses of real-world data and clinical trial data (in collaboration with biostatistics) to generate inputs including treatment effects, survival extrapolations, resource use, and health utility estimates.

• Design evidence synthesis, including network meta-analysis (NMA), and matching adjusted indirect comparisons (MAIC) to inform comparative effectiveness.

• Advanced degree (Masters or PhD) in health economics, econometrics, biostatistics, mathematics, engineering or related field (DrPH, PharmD).

• Minimum of 15 years with a Masters (or 13+ years with a PhD/PharmD/DrPH) of relevant experience in economic modeling in the pharmaceutical, biotech, or consulting setting.

• Hands on experience in developing cost-effectiveness, budget impact models as well as NMA/MAIC.

• Track record of high impact publications in economic modeling for global access decision-makers.

• Experience supporting HTA submissions and payer evidence generation.

• Strong written and interpersonal communication skills, with an ability to present complex technical information clearly.

• Proven leadership

• Ability to influence others without direct reporting relationships.

• Comfortable working in a global team across time zones.

• Experience in oncology economic modeling is highly desirable, especially related to gastrointestinal and thoracic malignancies.

The base pay salary range for this full-time position for candidates working onsite at our headquarters in Redwood City, CA is listed below. The range displayed on each job posting is intended to be the base pay salary range for an individual working onsite in Redwood City and will be adjusted for the local market a candidate is based in. Our base pay salary ranges are determined by role, level, and location. Individual base pay salary is determined by multiple factors, including job-related skills, experience, market dynamics, and relevant education or training.

Please note that base pay salary range is one part of the overall total rewards program at RevMed, which includes competitive cash compensation, robust equity awards, strong benefits, and significant learning and development opportunities.

View this job on nocollar jobs